ScholarIQanswers from OpenAlex & ORCID
Dean F. Bajorin
ResearcherPublications, citations & collaboration network
Dean F. Bajorin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Dean F. Bajorin have?
ScholarIQindexed works
Dean F. Bajorin has 863 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Dean F. Bajorin have?
ScholarIQcitation count
Dean F. Bajorin has 52,375 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Dean F. Bajorin?
ScholarIQh-index
Dean F. Bajorin has an h-index of 101 in OpenAlex.
What is the i10-index of Dean F. Bajorin?
ScholarIQi10-index
Dean F. Bajorin has an i10-index of 349 in OpenAlex.
What is the ORCID of Dean F. Bajorin?
ScholarIQorcid
The ORCID for Dean F. Bajorin is on the source record.
What is the OpenAlex record for Dean F. Bajorin?
ScholarIQopenalex
The OpenAlex for Dean F. Bajorin is on the source record.
What are the most-cited papers on Dean F. Bajorin?
ScholarIQmost cited works
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen, Yelena Y. Janjigian, David Barron, Ahmet Zehir, Emmet Jordan, Antonio Omuro, Thomas Kaley, Sviatoslav M. Kendall, Robert J. Motzer, A. Ari Hakimi, Martin H. Voss, Paul Russo, Jonathan E. Rosenberg, Gopa Iyer, Bernard H. Bochner, Dean F. Bajorin, Hikmat Al‐Ahmadie, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Shrujal S. Baxi, Alan L. Ho, Richard J. Wong, David G. Pfister, Jedd D. Wolchok, Christopher A. Barker, Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton, Ryan Ptashkin, Teng Gao, Lior Z. Braunstein, Sean M. Devlin, Daniel J. Kelly, Minal Patel, Antonin Berthon, Aijazuddin Syed, Mariko Yabe, Catherine C. Coombs, Nicole M. Caltabellotta, Mike Walsh, Kenneth Offit, Zsofia K. Stadler, Diana Mandelker, Jessica Schulman, Akshar Patel, John Philip, Elsa Bernard, Gunes Gundem, Juan Arango Ossa, Max F. Levine, Juan Martínez, Noushin Farnoud, Dominik Głodzik, Sonya Li, Mark E. Robson, Choonsik Lee, Paul D.P. Pharoah, Konrad H. Stopsack, Barbara Spitzer, Simon Mantha, James A. Fagin, Laura Boucai, Christopher J. Gibson, Benjamin L. Ebert, Andrew L. Young, Todd E. Druley, Koichi Takahashi, Nancy Gillis, Markus Ball, Eric Padron, David M. Hyman, José Baselga, Larry Norton, Stuart M. Gardos, Virginia M. Klimek, Howard I. Scher, Dean F. Bajorin, Eder Paraiso, Ryma Benayed, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, Martin S. Tallman, Montserrat García‐Closas, Nilanjan Chatterjee, Luis A. Díaz, Ross L. Levine, Lindsay M. Morton, Ahmet Zehir, Elli Papaemmanuil
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
Diana Mandelker, Liying Zhang, Yelena Kemel, Zsofia K. Stadler, Joseph Vijai, Ahmet Zehir, Nisha Pradhan, Angela G. Arnold, Michael F. Walsh, Yirong Li, Anoop R. Balakrishnan, Aijazuddin Syed, Meera Prasad, Khédoudja Nafa, Maria I. Carlo, Karen A. Cadoo, Meg Sheehan, Megan Harlan Fleischut, Erin Salo‐Mullen, Magan Trottier, Steven M. Lipkin, Anne Lincoln, Semanti Mukherjee, Vignesh Ravichandran, Roy Cambria, Jesse Galle, Wassim Abida, Marcia E. Arcila, Ryma Benayed, Ronak Shah, Kenneth H. Yu, Dean F. Bajorin, Jonathan Coleman, Steven D. Leach, Maeve A. Lowery, Julio García‐Aguilar, Philip W. Kantoff, Charles L. Sawyers, Maura N. Dickler, Leonard B. Saltz, Robert J. Motzer, Eileen M. O’Reilly, Howard I. Scher, José Baselga, David S. Klimstra, David B. Solit, David M. Hyman, Michael F. Berger, Marc Ladanyi, Mark E. Robson, Kenneth Offit